Soleno Therapeutics (NASDAQ:SLNO) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.06 by 754.55 percent. This is a 125.68 percent increase over losses of $(1.83) per share from the same period last year. The company reported quarterly sales of $66.000 million which beat the analyst consensus estimate of $48.095 million by 37.23 percent.